A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2a Study to Evaluate the Safety, Tolerability, and Early Proof of Concept of TAK-018 for the Prevention of Postoperative Crohn's Disease Recurrence
Status: Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 19 Nov 2019
Price : $35 *
At a glance
- Drugs EB 8018 (Primary)
- Indications Crohn's disease
- Focus Adverse reactions; Proof of concept
- Sponsors Takeda Oncology
- 12 Nov 2019 Planned initiation date changed from 4 Nov 2019 to 17 Feb 2020.
- 23 Oct 2019 Planned initiation date changed from 8 Oct 2019 to 4 Nov 2019.
- 27 Sep 2019 Planned initiation date changed from 20 Sep 2019 to 8 Oct 2019.